Mark J. Tebbe

Mark J. Tebbe

Chief Tech/Sci/R&D Officer at Newco (Canada)

Health Technology
Finance
Consumer Services

Profile

Mark is CTO of Matchpoint Therapeutics.
Formerly Mark was Co-Founder and CTO of Quench Bio and before that was VP, Head of Drug Discovery at Quartet Medicine.
Mark has >23 years of experience in drug discovery and development and is a co-inventor of Incivek (Telaprevir), an HCV protease inhibitor.
He was previously VP of Medicinal and Computational Chemistry at Forma Therapeutics where he focused on small molecule cancer therapeutics.
Prior to that, Mark held positions of increasing responsibility during his 16-year career at Eli Lilly including head of chemistry and Global Head of Operations for the discovery chemistry group.
He obtained his Ph.D.
in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame.

Mark J. Tebbe active positions

CompaniesPositionStart
Consultant / Advisor 2017-10-31
Chief Tech/Sci/R&D Officer 2023-05-31
All active positions of Mark J. Tebbe

Former positions of Mark J. Tebbe

CompaniesPositionEnd
Chief Tech/Sci/R&D Officer 2023-02-28
Chairman 2019-11-30
Consultant / Advisor 2010-05-31
Founder -
Corporate Officer/Principal -
See the detail of Mark J. Tebbe's experience

Training of Mark J. Tebbe

University of Notre Dame Undergraduate Degree
Stanford University Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark J. Tebbe's experience

Connections

86

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies8

Health Technology

Finance

Commercial Services

Health Technology

Finance

Health Technology

Health Technology

Finance

See company connections
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW